

Acuvi - Preparing for a Stronger H2

Redeye expected a bit more in terms of top-line growth in Q2, which was softer than we have seen recently. Q2 sales grew by 14% proforma (vs. Q1'22 of 31%). Adjusted EBITDA was quite modest but still in positive territory. Business activity is high and Acuvi is preparing for a stronger second half of 2022. Our positive view on the case is intact, but our forecast adjustments have some negative impact on valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Acuvi - Preparing for a Stronger H2](#)